Johnson & Johnson has won FDA approval for Symtuza, a new once-a-day HIV drug, but faces a crowded market that includes Gilead's hot-selling Biktarvy.
Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug picked up an FDA breakthrough designation in liver cancer.
Even before Pfizer faced Trump's wrath for July price hikes, Novartis decided increasing its own prices wouldn’t be prudent, its CEO said Wednesday.
Novartis, whose CAR-T cancer treatment Kymriah was approved less than a year ago, today it has run into some manufacturing issues.
Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.
More than six years after winning approval, obesity drug Belviq has shown it’s heart-safe, but will that help it sell?
But with six months down and six to go, Humira is on track to keep its pharma TV ad crown for 2018 with spending well ahead of 2017.
Evoke Group has acquired Giant Creative Strategy, adding new geograhy and expertise in its aggressive growth strategy.
Bayer's latest campaign rolls with hometown America to show the company's broad array of products and connections to consumers.